David A. Smith

2.8k total citations
26 papers, 893 citations indexed

About

David A. Smith is a scholar working on Oncology, Molecular Biology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, David A. Smith has authored 26 papers receiving a total of 893 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 8 papers in Molecular Biology and 5 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in David A. Smith's work include HER2/EGFR in Cancer Research (6 papers), Monoclonal and Polyclonal Antibodies Research (5 papers) and Colorectal Cancer Treatments and Studies (4 papers). David A. Smith is often cited by papers focused on HER2/EGFR in Cancer Research (6 papers), Monoclonal and Polyclonal Antibodies Research (5 papers) and Colorectal Cancer Treatments and Studies (4 papers). David A. Smith collaborates with scholars based in United States, United Kingdom and Malaysia. David A. Smith's co-authors include Mark L. Purnell, Norman Lindsay Harris, L. LaMoreaux, Thomas G. Lowe, Michael O’Brien, Lucas A. Wilson, Dale E. Shuster, Kumari Chandrawansa, P. L. Lantos and Antoinette R. Tan and has published in prestigious journals such as Journal of Clinical Oncology, Spine and The American Journal of Sports Medicine.

In The Last Decade

David A. Smith

26 papers receiving 870 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David A. Smith United States	13	356	321	219	160	155	26	893
Ulrika Segersten Sweden	20	474 1.3×	228 0.7×	288 1.3×	538 3.4×	83 0.5×	37	1.3k
Tsung‐Yen Cheng Taiwan	16	193 0.5×	378 1.2×	57 0.3×	264 1.6×	25 0.2×	20	723
Kim Leitzel United States	16	73 0.2×	451 1.4×	105 0.5×	294 1.8×	37 0.2×	55	791
Woon Yong Jung South Korea	18	145 0.4×	203 0.6×	70 0.3×	339 2.1×	44 0.3×	41	783
Rasesh Kapadia United States	13	118 0.3×	428 1.3×	35 0.2×	612 3.8×	237 1.5×	15	1.0k
Wen Ling United States	15	108 0.3×	589 1.8×	45 0.2×	579 3.6×	82 0.5×	45	1.2k
H Kanehiro Japan	11	320 0.9×	362 1.1×	15 0.1×	224 1.4×	42 0.3×	33	856
Arja Jukkola‐Vuorinen Finland	15	133 0.4×	202 0.6×	43 0.2×	196 1.2×	22 0.1×	40	687
P.R. Elford Switzerland	18	89 0.3×	448 1.4×	38 0.2×	678 4.2×	136 0.9×	24	1.2k
Billur Şamli United States	10	109 0.3×	247 0.8×	189 0.9×	137 0.9×	23 0.1×	13	596

Countries citing papers authored by David A. Smith

Since Specialization

Citations

This map shows the geographic impact of David A. Smith's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David A. Smith with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David A. Smith more than expected).

Fields of papers citing papers by David A. Smith

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David A. Smith. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David A. Smith. The network helps show where David A. Smith may publish in the future.

Co-authorship network of co-authors of David A. Smith

This figure shows the co-authorship network connecting the top 25 collaborators of David A. Smith. A scholar is included among the top collaborators of David A. Smith based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David A. Smith. David A. Smith is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Santana, Evelyn, et al.. (2024). Glial Cell Responses and Gene Expression Dynamics in Retinas of Treated and Untreated RPE65 Mutant Dogs. Investigative Ophthalmology & Visual Science. 65(12). 18–18. 1 indexed citations

Stewart, Tracy Murray, Daniel D. Von Hoff, Michael L. Fitzgerald, et al.. (2020). A Phase Ib multicenter, dose-escalation study of the polyamine analogue PG-11047 in combination with gemcitabine, docetaxel, bevacizumab, erlotinib, cisplatin, 5-fluorouracil, or sunitinib in patients with advanced solid tumors or lymphoma. Cancer Chemotherapy and Pharmacology. 87(1). 135–144. 15 indexed citations

Liu, Minetta C., Tara Maddala, Alex Aravanis, et al.. (2018). Breast cancer cell-free DNA (cfDNA) profiles reflect underlying tumor biology: The Circulating Cell-Free Genome Atlas (CCGA) study.. Journal of Clinical Oncology. 36(15_suppl). 536–536. 20 indexed citations

Smith, David A., Johan Vansteenkiste, Louis Fehrenbacher, et al.. (2016). Updated survival and biomarker analyses of a randomized phase II study of atezolizumab vs docetaxel in 2L/3L NSCLC (POPLAR).. Journal of Clinical Oncology. 34(15_suppl). 9028–9028. 22 indexed citations

Jimeno, Antonio, Kraig Moore, Michael S. Gordon, et al.. (2016). A first-in-man phase 1a study of the bispecific anti-DLL4/anti-VEGF antibody OMP-305B83 in patients with previously treated solid tumors. European Journal of Cancer. 69. S35–S35. 5 indexed citations

Piha‐Paul, Sarina A., James A. Knost, Fadi S. Braiteh, et al.. (2015). Genomic mutation profiling (GMP) and clinical outcome of patients treated with buparlisib (PI3K inhibitor) in the “Signature” program.. Journal of Clinical Oncology. 33(15_suppl). 2516–2516. 3 indexed citations

Jotte, Robert M., Daniel D. Von Hoff, Fadi Braiteh, et al.. (2014). An innovative, multi-arm, complete phase 1b study of the novel anti-cancer agent tasisulam in patients with advanced solid tumors. Investigational New Drugs. 33(1). 148–158. 10 indexed citations

Richards, Donald, Fadi S. Braiteh, Agustin A. García, et al.. (2014). A phase 1 study of MM-111, a bispecific HER2/HER3 antibody fusion protein, combined with multiple treatment regimens in patients with advanced HER2-positive solid tumors.. Journal of Clinical Oncology. 32(15_suppl). 651–651. 33 indexed citations

Becerra, Carlos, Jeffrey R. Infante, Lawrence Garbo, et al.. (2012). A five-arm, open-label, phase I/lb study to assess safety and tolerability of the oral MEK1/MEK2 inhibitor trametinib (GSK1120212) in combination with chemotherapy or erlotinib in patients with advanced solid tumors.. Journal of Clinical Oncology. 30(15_suppl). 3023–3023. 10 indexed citations

10.

Gold, Philip J., et al.. (2012). Phase II trial of panobinostat (LBH589) in patients (pts) with refractory metastatic colorectal cancer (MCRC).. Journal of Clinical Oncology. 30(4_suppl). 582–582. 3 indexed citations

11.

Cohn, Allen Lee, Pankaj Khandelwal, David A. Smith, et al.. (2011). An Open-label, Single-arm, Phase 2 Trial of Panitumumab Plus FOLFIRI as Second-line Therapy in Patients with Metastatic Colorectal Cancer. Clinical Colorectal Cancer. 10(3). 171–177. 33 indexed citations

12.

Socinski, Mark A., Robert N. Raju, Marcus A. Neubauer, et al.. (2008). Pemetrexed in Relapsed Small-Cell Lung Cancer and the Impact of Shortened Vitamin Supplementation Lead-In Time: Results of a Phase II Trial. Journal of Thoracic Oncology. 3(11). 1308–1316. 20 indexed citations

13.

Lowe, Thomas G., et al.. (2004). A Biomechanical Study of Regional Endplate Strength and Cage Morphology as It Relates to Structural Interbody Support. Spine. 29(21). 2389–2394. 175 indexed citations

14.

Merola, Andrew, Michael O’Brien, David A. Smith, et al.. (2002). Histologic Characterization of Acute Spinal Cord Injury Treated with Intravenous Methylprednisolone. Journal of Orthopaedic Trauma. 16(3). 155–161. 33 indexed citations

15.

Smith, David A.. (2002). Evaluation of Urinary Incontinence. Journal of the American Medical Directors Association. 3(Supplement 1). S2–S10. 5 indexed citations

16.

Harris, Norman Lindsay, David A. Smith, L. LaMoreaux, & Mark L. Purnell. (1997). Central Quadriceps Tendon for Anterior Cruciate Ligament Reconstruction. The American Journal of Sports Medicine. 25(1). 23–28. 172 indexed citations

17.

Smith, David A.. (1993). Using the new AACR 2 : an expert systems approach to choice of access points. 1 indexed citations

18.

Kay, Jasmine, et al.. (1985). Interference in Urea Determination by High Immunoglobulin Levels. Annals of Clinical Biochemistry International Journal of Laboratory Medicine. 22(2). 215–216. 2 indexed citations

19.

Smith, David A. & P. L. Lantos. (1985). Immunocytochemistry of cerebellar astrocytomas: with a special note on rosenthal fibres. Acta Neuropathologica. 66(2). 155–159. 22 indexed citations

20.

Fidler, I. J., S Sone, William E. Fogler, et al.. (1982). Efficacy of liposomes containing a lipophilic muramyl dipeptide derivative for activating the tumoricidal properties of alveolar macrophages in vivo. 1(1). 43–55. 55 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact